BRAIN Biotech AGHAM:BNN -0.35%65 Days Payable is 73.27 as of Mar. 2026, which is 13% below its 10-year median of 84.70. GuruFocus rates HAM:BNN with a GF Score™ of 65/100 and a GF Value™ of €2.56 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 1,555 Chemicals companies, BRAIN Biotech AG ranks better than 70.16% on this metric.
The historical rank and industry rank for BRAIN Biotech AG's Days Payable or its related term are showing as below:
HAM:BNN'
s Days Payable Range Over the Past 10 Years
Min: 70.88 Med: 84.7 Max: 94.98
Current: 86.99
During the past 11 years, BRAIN Biotech AG's highest Days Payable was 94.98. The lowest was 70.88. And the median was 84.70.
HAM:BNN's Days Payable is ranked better than 70.16% of 1555
companies
in the Chemicals industry
Industry Median: 59.95
vs HAM:BNN: 86.99
BRAIN Biotech AG's Days Payable
declined
from Mar. 2025 (101.99) to Mar. 2026 (73.27).
It may suggest that BRAIN Biotech AGaccelerated paying its suppliers.
BRAIN Biotech AG Days Payable Related Terms
BRAIN Biotech AG Days Payable Historical Data
* Premium members only.
The historical data trend for BRAIN Biotech AG's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Specialty Chemicals subindustry, BRAIN Biotech AG's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BRAIN Biotech AG Days Payable vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, BRAIN Biotech AG's Days Payable distribution charts can be found below:
* The bar in red indicates where BRAIN Biotech AG's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
BRAIN Biotech AG's Days Payable for the fiscal year that ended in Sep. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BRAIN Biotech AG (HAM:BNN) has a Days Payable of 73.27 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on BRAIN Biotech AG and its competitors. This is 13% below median its historical median of 84.70. Over the past decade, BRAIN Biotech AG's Days Payable has ranged from 70.88 to 94.98. According to the industry distribution chart, BRAIN Biotech AG ranks #464 out of 1555 companies in the Chemicals industry, placing it in the top 29.8%.
Is BRAIN Biotech AG's Days Payable too high?
BRAIN Biotech AG's current Days Payable of 73.27 is 13% below median its 10-year median of 84.70. Over the past 10 years, this metric has ranged from a low of 70.88 to a high of 94.98. The Chemicals industry median Days Payable is 59.95. BRAIN Biotech AG's value of 73.27 is 22.2% above this industry median. Based on the distribution chart, BRAIN Biotech AG ranks #464 out of 1555 companies in the Chemicals industry, which is above the industry midpoint. Overall, BRAIN Biotech AG has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BRAIN Biotech AG's Days Payable compare to LIN and SHW?
According to the Chemicals industry distribution chart, BRAIN Biotech AG ranks #464 out of 1555 companies for Days Payable. This puts BRAIN Biotech AG in the upper half of its industry. The industry median Days Payable is 59.95. BRAIN Biotech AG's value of 73.27 is 22.2% above this benchmark. Historically, BRAIN Biotech AG's own Days Payable has ranged from 70.88 to 94.98 over the past decade. While the company's 10-year median is 84.70 vs. the industry median of 59.95, BRAIN Biotech AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Chemicals company?
The median Days Payable among Chemicals companies is 59.95, based on 1,555 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BRAIN Biotech AG's current Days Payable of 73.27 is 22.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on BRAIN Biotech AG and its competitors. For the Chemicals industry, the median Days Payable is 59.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BRAIN Biotech AG's current Days Payable is 73.27, which is 13% below median its own 10-year median of 84.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BRAIN Biotech AG stock overvalued right now?
Based on GuruFocus' analysis, BRAIN Biotech AG (HAM:BNN) is currently considered Modestly Overvalued. The stock's GF Value™ is €2.56, compared to a current price of €2.85 — trading 11.3% above its estimated fair value. The current Days Payable is 73.27, which is 13% below median its 10-year median of 84.70 and 22.2% above the Chemicals industry median of 59.95. BRAIN Biotech AG's overall GF Score™ is 65/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For BRAIN Biotech AG (HAM:BNN), the current Days Payable is 73.27 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BRAIN Biotech AG (HAM:BNN) Overvalued in 2026?
Based on GuruFocus' analysis, BRAIN Biotech AG stock appears to be overvalued.
The current stock price of €2.85 is trading 11.3% above its estimated GF Value™ of €2.56.
GuruFocus considers BRAIN Biotech AG to be Modestly Overvalued.
Key valuation signals for HAM:BNN:
Days Payable: 73.27 (13% below median its 10-year median of 84.70)
GF Value™: €2.56 vs. price of €2.85 (11.3% above fair value)
Industry Position: 22.2% above the Chemicals median (#464 of 1555)
No single metric tells the full story. See the HAM:BNN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BRAIN Biotech AG is an industrial biotechnology specialist focused on enzyme technology, microbial production strains, and bioprocess design to enable bio-based innovations. The Group conducts research, development, and production for client specifications and its own product portfolio, supporting customers in the food and beverage, chemical, and life sciences industries with solutions that enhance productivity, efficiency, and sustainability. Its operations are organized into two segments: BRAIN Biocatalysts, which develops, produces, and distributes specialty enzymes, microorganisms, and ingredients and generates the majority of revenue, and BRAIN BioIncubator, which focuses on development projects. The company operates in Germany and other countries.
65GF Score
Get the complete analysis for HAM:BNN
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:BNN has been successfully added to your 
